20 Countries with the Highest Cancer Survival Rates in the World
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Engineering a Cool Career in Biotech - and Volunteering Along the Way
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
Microsoft-Backed Rubrik Seeks Up to $713 Million in IPO
European Commission approves Illumina’s proposed Grail split
Rubrik Is Seeking IPO of as Much as $713 Million
Illumina's planned divestment of GRAIL approved by the European Commission
UPDATE 1-EU approves Illumina's plan to divest cancer test maker Grail
EU approves Illumina's plan to divest cancer test maker Grail
EU approves Illumina's plan to divest cancer test maker Grail
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
Illumina CFO steps down amid executive shakeup
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.